⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7756647 | 1.00 | — | — | |
| SCHEMBL8744207 | 0.87 | HSD17B10 (0.38) | — | |
| SCHEMBL8744210 | 0.87 | HSD17B10 (0.38) | — | |
| SCHEMBL13179378 | 0.87 | HSD17B10 (0.38) | — | |
| SCHEMBL9474466 | 0.86 | TSHR (0.50) | — | |
| SCHEMBL5440335 | 0.86 | TSHR (0.50) | — | |
| SCHEMBL13889961 | 0.86 | TSHR (0.50) | — | |
| SCHEMBL7755361 | 0.84 | HTT (0.48) | — | |
| SCHEMBL8601689 | 0.84 | HTT (0.48) | — | |
| SCHEMBL27514818 | 0.84 | HSD17B10 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112933234-A | Repeated administration of non-immunosuppressive antigen-specific immunotherapeutics | 西莱克塔生物科技公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-112933218-A | Repeated administration of non-immunosuppressive antigen-specific immunotherapeutics | 西莱克塔生物科技公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-111686255-A | Delivery of immunosuppressants and antigens with specific pharmacodynamic effective duration for induction of immune tolerance | 西莱克塔生物科技公司 | 2020-09-22 | — | — | CN | disclosed |
| CN-111068061-A | Administration combination for reducing undesired humoral immune responses | 西莱克塔生物科技公司 | 2020-04-28 | — | — | CN | disclosed |
| CN-111053908-A | Administration combination for reducing undesired humoral immune responses | 西莱克塔生物科技公司 | 2020-04-24 | — | — | CN | disclosed |
| CN-110841067-A | Tolerogenic synthetic nanocarriers and therapeutic macromolecules for reduced or enhanced pharmacodynamic effects | 西莱克塔生物科技公司 | 2020-02-28 | — | — | CN | disclosed |
| CN-110841066-A | Tolerogenic synthetic nanocarriers and therapeutic macromolecules for reduced or enhanced pharmacodynamic effects | 西莱克塔生物科技公司 | 2020-02-28 | — | — | CN | disclosed |
| CN-110694077-A | Methods and compositions for enhancing CD4+ regulatory T cells | 西莱克塔生物科技公司 | 2020-01-17 | — | — | CN | disclosed |
| CN-110639024-A | Methods and compositions for enhancing CD4+ regulatory T cells | 西莱克塔生物科技公司 | 2020-01-03 | — | — | CN | disclosed |